biostudies-literatureGebrecherkos TEuropean & Developing Countries Clinical Trials Partnership (EDCTP)e0263627https://www.ebi.ac.uk/biostudies/studies/S-EPMC8942258biostudies-literatureUnknown17(3)<h4>Background</h4>Serological testing for SARS-CoV-2 plays an important role for epidemiological studies, in aiding the diagnosis of COVID-19, and assess vaccine responses. Little is known on dynamics of SARS-CoV-2 serology in African settings. Here, we aimed to characterize the longitudinal antibody response profile to SARS-CoV-2 in Ethiopia.<h4>Methods</h4>In this prospective study, a total of 102 PCR-confirmed COVID-19 patients were enrolled. We obtained 802 plasma samples collected serially. SARS-CoV-2 antibodies were determined using four lateral flow immune-assays (LFIAs), and an electrochemiluminescent immunoassay. We determined longitudinal antibody response to SARS-CoV-2 as well as seroconversion dynamics.<h4>Results</h4>Serological positivity rate ranged between 12%-91%, dependiPloS oneLongitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.PMC8942258RIA-2020EF-2095Abdulkader MUrban BCTessema MKiros YKKifle TTollera GChalla FTasew GDesta Ade Wit TFRAbdella SGebrecherkos TSchallig HHWolday DHailu AGebreegzabher ALeta DArefaine ZGAdams ERfalseLongitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study.<h4>Background</h4>Serological testing for SARS-CoV-2 plays an important role for epidemiological studies, in aiding the diagnosis of COVID-19, and assess vaccine responses. Little is known on dynamics of SARS-CoV-2 serology in African settings. Here, we aimed to characterize the longitudinal antibody response profile to SARS-CoV-2 in Ethiopia.<h4>Methods</h4>In this prospective study, a total of 102 PCR-confirmed COVID-19 patients were enrolled. We obtained 802 plasma samples collected serially. SARS-CoV-2 antibodies were determined using four lateral flow immune-assays (LFIAs), and an electrochemiluminescent immunoassay. We determined longitudinal antibody response to SARS-CoV-2 as well as seroconversion dynamics.<h4>Results</h4>Serological positivity rate ranged between 12%-91%, dependi2022-01-01T00:00:00Z20222026-05-31T01:00:12.667Z2025-05-18T12:30:53.735ZS-EPMC89422583532028610.1371/journal.pone.0263627